Argatroban e368 Fibrinolytic Therapy in Patients With Definite NSTE-ACS: Recommendation . e368 Ischemia-Guided Strategy Versus Early Invasive Strategies e368 4.4.1. General Principles e368 Rationale and Timing for Early Invasive Strategy e368 Routine Invasive Strategy Timing e368 ACC/AHA TASK FORCE MEMBERS Jeffrey L. Anderson, MD, FACC, FAHA, Chair; Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect; Nancy M. Albert, PhD, RN, FAHA; Biykem Bozkurt, MD, PhD, FACC, FAHA; Ralph G. Brindis, MD, MPH, MACC; Lesley H. Curtis, PhD, FAHA; David DeMets, PhD ; Lee A. Fleisher, MD, FACC, FAHA; Samuel Gidding, MD, FAHA; Robert A. Guyton, MD, FACC ; Judith S. Hochman, MD, FACC, FAHA ; Richard J. Kovacs, MD, FACC, FAHA; E. Magnus Ohman, MD, FACC; Susan J. Pressler, PhD, RN, FAHA; Frank W. Sellke, MD, FACC, FAHA; Win-Kuang Shen, MD, FACC, FAHA; William G. Stevenson, MD, FACC, FAHA ; Duminda N. Wijeysundera, MD, PhD; Clyde W. Yancy, MD, FACC, FAHA Rationale for Ischemia-Guided Strategy e368 Early Invasive and Ischemia-Guided Strategies: Recommendations e368 Comparison of Early Versus Delayed Angiography e370 Subgroups: Early Invasive Strategy Versus Ischemia-Guided Strategy e371 4.4.6. Care Objectives e371 Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS: Recommendations e371 4.5.1. Noninvasive Test Selection e371 4.5.2. Selection for Coronary Angiography e372 5. Myocardial Revascularization e372 5.1. Percutaneous Coronary Intervention e372 5.1.1. PCI General Considerations: Recommendation e372 5.1.2. PCI Antiplatelet and Anticoagulant Therapy e372 Oral and Intravenous Antiplatelet Agents: Recommendations e372 GP IIb/IIIa Inhibitors: Recommendations e373 5.1.2.3. 